Theophylline ER

Phase 2Small molecule

UUniversity of California, Los Angeles

Theophylline ER is one of 2 small molecule programs targeting Pseudohypoparathyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PseudohypoparathyroidismEnrolling by invitation

PseudohypoparathyroidismPhase 2

Enrolling by invitation

Competition

Competitive Landscape

1 competitor in Pseudohypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Phase 2

1 2

Theophylline ER

UUniversity of California, Los Angeles

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD

Completed·UUniversity of Miami·Phase 3·NCT03984188·100 enrolled

Depression1 trial

Theophylline for Depression Study

Withdrawn·UUniversity of California, Los Angeles·Phase 1·NCT04309877

Pseudohypoparathyroidism1 trial

Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism

Enrolling by invitation·AAshley Shoemaker·Phase 2·NCT04240821·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Theophylline ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Theophylline ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Theophylline ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, Los Angeles

Theophylline ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

Depression1 trial

Pseudohypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News